The present Competitive Intelligence report about Kallikrein Inhibitors and bradykinin receptor antagonists provides a competitor evaluation in the field of marketed drugs and novel approaches for prophylaxis and treatment of hereditary angioedema (HAE) and new investigational compounds for treatment of diabetic macular edema (DME) as of April 2017.
Inhibitors of kallikrein and antagonists of the bradykinin receptors are based on small molecules, antibodies, proteins, peptides as well as RNA. Based on the commercial success of marketed drugs for prophylaxis of HAE, next generation molecules were designed to improve convenience of mode of administration and frequency of administration. In addition, the use of kallikrein inhibitors for ophthalmic indications is being evaluated with the most advanced compounds in clinical studies.
The report includes a compilation of currently active projects in research and development of small molecule, antibody, protein, peptide and oligonucleotide inhibitors ofkallikrein. In addition, the report lists company-specific R&D pipelines of plasma and tissue kallikrein inhibitors.
Competitor projects are listed in a tabular format providing information on:
- Drug Codes
- Target/Mechanism of Action
- Class of Compound
- Product Category
- R&D Stage
- Additional comments with a hyperlink leading to the source of information.
Key Topics Covered:
1. Kallikrein Inhibitors 2017
- Plasma Kallikrein Inhibitors for Hereditary Angioedema
- Plasma Kallikrein Inhibitors for Diabetic Macular Edema
- Tissue Kallikrein Inhibitors
2. Corporate Kallikrein Inhibitor R&D Pipelines
For more information about this report visit https://www.researchandmarkets.com/research/f4c6gd/competitor